|By PR Newswire||
|March 11, 2014 06:30 AM EDT||
SAN ANTONIO, March 11, 2014 /PRNewswire/ -- Aperion Biologics, Inc., a clinical-stage regenerative medical device company, announced that France Dixon Helfer and Mike Ward were appointed to the Company's Board of Directors.
Ms. Helfer currently serves as President and Chief Executive Officer of Halo Healthcare Inc., a medical device and diagnostics company which develops innovative technologies for early risk detection of breast cancer. Most recently, she was the founder and CEO of Pegasus Biologics where she raised $32M, and in less than three years, built the company into an emerging growth revenue company with a solid product pipeline, acquired by Synovis Life Systems and more recently, Baxter. Ms. Helfer has held a number of executive level positions at Medtronic, Xenotech Labs (founding employee, acquired by Medtronic), SORIN Biomedica, Eclipse Surgical (IPO), and MDDataDirect. Ms. Helfer currently serves on several boards and as a strategic advisor to medical companies, including Board member of Epic Diagnostics and Epic Medical (UCLA) , an advisor to Neural Analytics (UCLA), Reviticell Holdings, and MLM Biologics. She's a strong advocate for female executives in healthcare and is an advisor to HBA, and a frequent lecturer on entrepreneurship and leadership.
Mike Ward has over 20 years of life sciences-dedicated investment banking, venture capital and private equity experience. During his career in investment banking, Mr. Ward executed over 80 life sciences M&A and financing transactions. Mr. Ward serves on the boards of the following life sciences companies: Nanosphere, Inc., a targeted molecular diagnostics company based in Northbrook, IL, and CytoPherx, Inc., an acute renal failure-focused therapeutic medical device company based in Ann Arbor, MI. Mr. Ward was previously a Director at Lurie Investments, Inc. where he was responsible for managing investment activities. Prior to joining Lurie Investments in 2009, Mr. Ward gained over 15 years of investment banking experience at Credit Suisse, Prudential Securities, Dresdner Kleinwort Wasserstein, BMO and Leerink Swann.
"France and Mike bring a wealth of experience, from private equity, venture capital, entrepreneurship, product development, and business development," said Daniel Lee, Chief Executive Officer of the Company. "Their extraordinary industry experience will be a huge asset to the company as we move forward with our Z-Lig™ device, the first non-human biologic device for anterior cruciate ligament (ACL) reconstruction of the knee."
About Aperion Biologics, Inc.
Aperion Biologics, Inc., located in San Antonio, Texas, is a privately owned, clinical-stage medical device company addressing the need for alternatives to human-based grafts with animal-based tissue technology. Aperion developed and patented a technique to make animal tissues compatible for challenging human applications. This creates functioning scaffolds capable of remodeling into healthy tissue. Aperion's Z-Process™ is applicable to a variety of tissues used in orthopaedic, cardiovascular, plastic, dermatologic, general and other surgical specialties. The company's lead product for ligament reconstruction procedures, the Z-Lig™ ACLR Device, is currently in clinical investigation and the company has applied for the CE Mark to enable commercialization in the European market.
SOURCE Aperion Biologics, Inc.
DevOps theory promotes a culture of continuous improvement built on collaboration, empowerment, systems thinking, and feedback loops. But how do you collaborate effectively across the traditional silos? How can you make decisions without system-wide visibility? How can you see the whole system when it is spread across teams and locations? How do you close feedback loops across teams and activities delivering complex multi-tier, cloud, container, serverless, and/or API-based services?
Oct. 24, 2016 03:30 AM EDT Reads: 1,043
SYS-CON Media announced today that @WebRTCSummit Blog, the largest WebRTC resource in the world, has been launched. @WebRTCSummit Blog offers top articles, news stories, and blog posts from the world's well-known experts and guarantees better exposure for its authors than any other publication. @WebRTCSummit Blog can be bookmarked ▸ Here @WebRTCSummit conference site can be bookmarked ▸ Here
Oct. 24, 2016 03:30 AM EDT Reads: 9,668
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his session at @DevOpsSummit 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will show how customers are able to achieve a level of transparency that enables everyon...
Oct. 24, 2016 03:15 AM EDT Reads: 1,283
Oct. 24, 2016 02:45 AM EDT Reads: 1,098
Oct. 24, 2016 02:30 AM EDT Reads: 1,047
Oct. 24, 2016 02:15 AM EDT Reads: 830
Oct. 24, 2016 01:15 AM EDT Reads: 3,925
Oct. 24, 2016 01:15 AM EDT Reads: 1,887
Oct. 24, 2016 01:00 AM EDT Reads: 781
Oct. 24, 2016 01:00 AM EDT Reads: 3,572
Oct. 24, 2016 12:45 AM EDT Reads: 964
Oct. 24, 2016 12:45 AM EDT Reads: 2,481
Oct. 24, 2016 12:45 AM EDT Reads: 760
Oct. 24, 2016 12:45 AM EDT Reads: 1,347
Oct. 24, 2016 12:15 AM EDT Reads: 884